The CEO and founder of deep-tech company Chemify, Lee Cronin, has published three peer-reviewed research papers collectively demonstrating how Chemputation can digitise chemistry to enable AI-driven molecular discovery, automated synthesis from scientific literature and application to cancer drug development.
The three papers were published in PNAS, Nature Communications Chemistry and Nature Communications Biology and discuss how the Chemputation AI platform can comprehend and execute instructions from scientific literature to iteratively create new molecules.
They also explore potential applications of this technology in cancer research.
"Chemputation has been established as a new paradigm, critical for the future of chemical discovery and manufacture and I'm proud that Chemify is building on these discoveries, delivering real molecules using Chemputation AI to our partners," said Lee Cronin, CEO and founder of Chemify.
Chemputation shifts chemistry from an artisanal practice to an executable, verifiable and shareable technology and opens the door to a future where drugs, materials and entirely new and makeable molecules can be designed, compiled and manufactured as easily as software.
The three papers were all published within two weeks of each other by Lee Cronin and multidisciplinary co-authors from the University of Glasgow, where Cronin has a lab.
The Proceedings of the National Academy of Sciences publication from April 7, "Chemputer and chemputation — A universal chemical compound Synthesis Machine," presents a new proof that chemical molecules can be synthesised using chemputation, opening the way to using a single programming language to make molecules.
The Nature Communications Chemistry publication from April 3, "Verification and execution of the scientific literature via chemputation augmented by large language models," describes how a system of agents is used to both read and correct the chemical literature so that the procedures can be safely used by robots capable of Chemputation to autonomously make the molecules and verify the process.
The Nature Communications Biology publication from March 27, "Chemical programming of kinase inhibitors in a modular chemputer-based system," shows how the Chemputation system can be used to iterate on new potential cancer treatments based on targeting a model of KRAS-mutant colorectal cancer in a practical example of how Chemputation is being applied to address challenges in preclinical drug discovery.